461 related articles for article (PubMed ID: 25667267)
1. Antibodies against hemolysin and cytotoxic necrotizing factor type 1 (CNF1) reduce bladder inflammation in a mouse model of urinary tract infection with toxigenic uropathogenic Escherichia coli.
Smith MA; Weingarten RA; Russo LM; Ventura CL; O'Brien AD
Infect Immun; 2015 Apr; 83(4):1661-73. PubMed ID: 25667267
[TBL] [Abstract][Full Text] [Related]
2. Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice.
Smith YC; Rasmussen SB; Grande KK; Conran RM; O'Brien AD
Infect Immun; 2008 Jul; 76(7):2978-90. PubMed ID: 18443089
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic necrotizing factor 1 and hemolysin from uropathogenic Escherichia coli elicit different host responses in the murine bladder.
Garcia TA; Ventura CL; Smith MA; Merrell DS; O'Brien AD
Infect Immun; 2013 Jan; 81(1):99-109. PubMed ID: 23090961
[TBL] [Abstract][Full Text] [Related]
4. Mutation of the gene encoding cytotoxic necrotizing factor type 1 (cnf(1)) attenuates the virulence of uropathogenic Escherichia coli.
Rippere-Lampe KE; O'Brien AD; Conran R; Lockman HA
Infect Immun; 2001 Jun; 69(6):3954-64. PubMed ID: 11349064
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic Necrotizing Factor-1 (CNF1) does not promote E. coli infection in a murine model of ascending pyelonephritis.
Michaud JE; Kim KS; Harty W; Kasprenski M; Wang MH
BMC Microbiol; 2017 May; 17(1):127. PubMed ID: 28545489
[TBL] [Abstract][Full Text] [Related]
6. Specificity of immunomodulator secretion in urinary samples in response to infection by alpha-hemolysin and CNF1 bearing uropathogenic Escherichia coli.
Real JM; Munro P; Buisson-Touati C; Lemichez E; Boquet P; Landraud L
Cytokine; 2007 Jan; 37(1):22-5. PubMed ID: 17382555
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic Necrotizing Factor 1 Downregulates CD36 Transcription in Macrophages to Induce Inflammation During Acute Urinary Tract Infections.
Yang H; Li Q; Wang C; Wang J; Lv J; Wang L; Zhang ZS; Yao Z; Wang Q
Front Immunol; 2018; 9():1987. PubMed ID: 30233583
[TBL] [Abstract][Full Text] [Related]
8. Intramacrophage survival of uropathogenic Escherichia coli: differences between diverse clinical isolates and between mouse and human macrophages.
Bokil NJ; Totsika M; Carey AJ; Stacey KJ; Hancock V; Saunders BM; Ravasi T; Ulett GC; Schembri MA; Sweet MJ
Immunobiology; 2011 Nov; 216(11):1164-71. PubMed ID: 21802164
[TBL] [Abstract][Full Text] [Related]
9. Virulence factors and O groups of Escherichia coli isolates from patients with acute pyelonephritis, cystitis and asymptomatic bacteriuria.
Blanco M; Blanco JE; Alonso MP; Blanco J
Eur J Epidemiol; 1996 Apr; 12(2):191-8. PubMed ID: 8817199
[TBL] [Abstract][Full Text] [Related]
10. Cathelicidin augments epithelial receptivity and pathogenesis in experimental Escherichia coli cystitis.
Danka ES; Hunstad DA
J Infect Dis; 2015 Apr; 211(7):1164-73. PubMed ID: 25336727
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis.
Davis JM; Carvalho HM; Rasmussen SB; O'Brien AD
Infect Immun; 2006 Aug; 74(8):4401-8. PubMed ID: 16861625
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2017 Sep; 110():477-483. PubMed ID: 28754265
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of haemolytic Escherichia coli with particular reference to production of cytotoxic necrotizing factor type 1 (CNF1).
Blanco J; Blanco M; Alonso MP; Blanco JE; González EA; Garabal JI
Res Microbiol; 1992; 143(9):869-78. PubMed ID: 1363736
[TBL] [Abstract][Full Text] [Related]
14.
Stærk K; Grønnemose RB; Nielsen TK; Petersen NA; Palarasah Y; Torres-Puig S; Møller-Jensen J; Kolmos HJ; Lund L; Andersen TE
Microbiology (Reading); 2021 Oct; 167(10):. PubMed ID: 34623231
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of hemolytic, cytotoxic necrotizing factor 1-positive and -negative Escherichia coli to human T24 bladder cells.
Island MD; Cui X; Foxman B; Marrs CF; Stamm WE; Stapleton AE; Warren JW
Infect Immun; 1998 Jul; 66(7):3384-9. PubMed ID: 9632609
[TBL] [Abstract][Full Text] [Related]
16. Intracellular uropathogenic Escherichia coli are undetectable in urinary bladders after oral mecillinam treatment: An experimental study in a pig model of cystitis.
Stærk K; Grønnemose RB; Palarasah Y; Lund L; Andersen TE
Microb Pathog; 2022 Dec; 173(Pt A):105817. PubMed ID: 36244593
[TBL] [Abstract][Full Text] [Related]
17. UTI patients have pre-existing antigen-specific antibody titers against UTI vaccine antigens.
Sarkissian CA; Alteri CJ; Mobley HLT
Vaccine; 2019 Aug; 37(35):4937-4946. PubMed ID: 31320216
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice.
Asadi Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S
Vaccine; 2013 Feb; 31(8):1210-6. PubMed ID: 23306365
[TBL] [Abstract][Full Text] [Related]
19. YbcL of uropathogenic Escherichia coli suppresses transepithelial neutrophil migration.
Lau ME; Loughman JA; Hunstad DA
Infect Immun; 2012 Dec; 80(12):4123-32. PubMed ID: 22966043
[TBL] [Abstract][Full Text] [Related]
20. Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection.
Forsyth VS; Himpsl SD; Smith SN; Sarkissian CA; Mike LA; Stocki JA; Sintsova A; Alteri CJ; Mobley HLT
mBio; 2020 Apr; 11(2):. PubMed ID: 32345645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
